Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk's weight loss drug, cagrisema, failed to meet investor expectations of achieving 25% weight loss, causing the stock to plummet. Galectin's stock also tumbled after its lead asset missed the primary endpoint in a phase IIb/III trial. On a positive note, Ionis' Tryngolza became the first FDA-approved therapy for familial chylomicronemia syndrome. GSK posted mixed survival data for the Jemperli/Zejula combo in first-line ovarian cancer treatment. Intelligencia AI accurately predicted high-potential biotechs before the ASH conference, showcasing the reliability of its AI-driven methodology. Overall, the biopharma industry is seeing a mix of successes and setbacks in various drug developments and approvals.